IBA - TRANSPARENCY NOTIFICATION
Louvain-la-Neuve, Belgium, January 12, 2018, 17.35 - IBA (Ion Beam Applications SA), the world`s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 12, 2018.
|Reason for the notification||Upwards crossing of the 3% threshold further to the acquisition of shares -and thus voting rights- held as loan collateral|
|Persons subject to the notification requirement||IBA SA, issuer|
|Persons that dispose of voting rights||Kempen Capital Management NV|
|Threshold that is crossed (in %)|| 3% |
Upwards crossing further to the acquisition of voting rights
|Denominator||29 962 246|
|Voting rights (number)||900 174|
|Voting rights (%)||3,00%|
|Chain of control||Van Lanschot Kempen N.V. < 100%> F. van Lanschot Banklers NV <100%> kempen & Co NV <100%> Kempen Capital Management NV. Kempen se réfère à la declaration d`indépendance (datée du 15 novembre 2017).|
|Additional information||Kempen Capital Management NV appeals for Art. 11 of the (Transparency) Law (May 2, 2007), by which an exemption is acquired.|
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA`s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
+32 10 203 924